title: Background and rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. SUpplementation en VItamines et Minéraux AntioXydants Study.
abstract: The "SUpplementation en VItamines et MinérauxAntioXydants" (SU.VI.MAX) study is a randomized double-blind, placebo-controlled, primary prevention trial designed to test the efficacy of daily supplementation with antioxidant vitamins (vitamin C, 120 mg; vitamin E, 30 mg; and beta-carotene, 6 mg) and minerals (selenium, 100 micrograms; and zinc, 20 mg), at nutritional doses (one to three times the daily recommended dietary allowances), in reducing the frequency of major health problems in industrialized countries, and especially the main causes of premature death (cancers and cardiovascular diseases). The study involves 12,735 eligible subjects (women aged 35 to 60 years; men aged 45 to 60 years) included in 1994 in France. They will be followed up for 8 years. The objectives and the specific design of this intervention study are linked to its public health aim. The targeted population is the general population (not simply high-risk subjects) and the antioxidant agents tested are being administered at a level which is not pharmacologic and which may be attained by dietary intake of natural sources of these micronutrients and/or enriched foods. The amounts we are testing in the SU.VI.MAX study are those which, in observational studies have been associated with the lowest risk of diseases. This report presents the rationale and discusses the justification of the design, doses and combination of antioxidant micronutrients chosen in the SU.VI.MAX study.
authors.affiliation: Institut Scientifique et Technique de la Nutrition et de l'Alimentation/CNAM, Paris.
authors.forename: S
authors.initials: S
authors.lastname: Hercberg
authors.forename: P
authors.initials: P
authors.lastname: Galan
authors.forename: P
authors.initials: P
authors.lastname: Preziosi
authors.forename: A M
authors.initials: AM
authors.lastname: Roussel
authors.forename: J
authors.initials: J
authors.lastname: Arnaud
authors.forename: M J
authors.initials: MJ
authors.lastname: Richard
authors.forename: D
authors.initials: D
authors.lastname: Malvy
authors.forename: A
authors.initials: A
authors.lastname: Paul-Dauphin
authors.forename: S
authors.initials: S
authors.lastname: Briançon
authors.forename: A
authors.initials: A
authors.lastname: Favier
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000592:standards / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000517:prevention & control*; D011322:Primary Prevention; D014131:Trace Elements / Q000592:standards / Q000627:therapeutic use*; D014815:Vitamins / Q000592:standards / Q000627:therapeutic use*
chemical_list: D000975:Antioxidants; D014131:Trace Elements; D014815:Vitamins